Cargando…
microRNA-371a-3p as informative biomarker for the follow-up of testicular germ cell cancer patients
PURPOSE: α-fetoprotein (AFP) and human chorionic gonadotropin subunit beta (B-HCG) are informative serum biomarkers for the primary diagnosis and follow-up of testicular germ cell cancer (TGCC) patients. About 20% of TGCC patients with a non-seminoma (NS) and about 80% with a seminoma (SE) are, howe...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537315/ https://www.ncbi.nlm.nih.gov/pubmed/28612337 http://dx.doi.org/10.1007/s13402-017-0333-9 |
_version_ | 1783254150206717952 |
---|---|
author | van Agthoven, Ton Eijkenboom, Wil M. H. Looijenga, Leendert H. J. |
author_facet | van Agthoven, Ton Eijkenboom, Wil M. H. Looijenga, Leendert H. J. |
author_sort | van Agthoven, Ton |
collection | PubMed |
description | PURPOSE: α-fetoprotein (AFP) and human chorionic gonadotropin subunit beta (B-HCG) are informative serum biomarkers for the primary diagnosis and follow-up of testicular germ cell cancer (TGCC) patients. About 20% of TGCC patients with a non-seminoma (NS) and about 80% with a seminoma (SE) are, however, negative for these biomarkers. Embryonic stem cell microRNAs (miRs) may serve as promising alternative serum biomarkers. Here we investigated a retrospective series of serum samples from selected TGCC patients who developed a relapse in time to test the possible additional value of the serum-based ampTSmiR test compared to the conventional serum-based protein biomarkers for follow-up. METHODS: We investigated 261 retrospective serum samples of six selected fully evaluated TGCC patients with a proven relapse using the ampTSmiR test for miR-371a-3p, miR-373-3p, and miR-367-3p and compared the results to those of the conventional protein biomarkers. RESULTS: At primary diagnosis, elevated serum B-HCG, AFP and LDH levels were found to be informative in 4/6, 3/6 and 3/6 patients, respectively. At primary diagnosis the levels of miR-371a-3p and miR-373-3p were elevated in 4/4, and miR-367-3p in 3/4 patients. For two cases no starting serum sample was available for retrospective miR analysis. Residual disease (overlooked by histopathological examination) was detected in one case by miR-371a-3p only. The miR-371a-3p level was increased in one patient two months before detection of an intracranial metastasis. B-HCG was informative in 3/4 and the ampTSmiR test in 4/4 patients with a relapse or residual disease. None of the biomarkers were informative for the detection of residual mature teratoma. CONCLUSIONS: The ampTSmiR test is more sensitive than the conventional TGCC protein biomarkers for the detection of residual disease and relapse, excluding mature teratoma. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13402-017-0333-9) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5537315 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer Netherlands |
record_format | MEDLINE/PubMed |
spelling | pubmed-55373152017-08-15 microRNA-371a-3p as informative biomarker for the follow-up of testicular germ cell cancer patients van Agthoven, Ton Eijkenboom, Wil M. H. Looijenga, Leendert H. J. Cell Oncol (Dordr) Original Paper PURPOSE: α-fetoprotein (AFP) and human chorionic gonadotropin subunit beta (B-HCG) are informative serum biomarkers for the primary diagnosis and follow-up of testicular germ cell cancer (TGCC) patients. About 20% of TGCC patients with a non-seminoma (NS) and about 80% with a seminoma (SE) are, however, negative for these biomarkers. Embryonic stem cell microRNAs (miRs) may serve as promising alternative serum biomarkers. Here we investigated a retrospective series of serum samples from selected TGCC patients who developed a relapse in time to test the possible additional value of the serum-based ampTSmiR test compared to the conventional serum-based protein biomarkers for follow-up. METHODS: We investigated 261 retrospective serum samples of six selected fully evaluated TGCC patients with a proven relapse using the ampTSmiR test for miR-371a-3p, miR-373-3p, and miR-367-3p and compared the results to those of the conventional protein biomarkers. RESULTS: At primary diagnosis, elevated serum B-HCG, AFP and LDH levels were found to be informative in 4/6, 3/6 and 3/6 patients, respectively. At primary diagnosis the levels of miR-371a-3p and miR-373-3p were elevated in 4/4, and miR-367-3p in 3/4 patients. For two cases no starting serum sample was available for retrospective miR analysis. Residual disease (overlooked by histopathological examination) was detected in one case by miR-371a-3p only. The miR-371a-3p level was increased in one patient two months before detection of an intracranial metastasis. B-HCG was informative in 3/4 and the ampTSmiR test in 4/4 patients with a relapse or residual disease. None of the biomarkers were informative for the detection of residual mature teratoma. CONCLUSIONS: The ampTSmiR test is more sensitive than the conventional TGCC protein biomarkers for the detection of residual disease and relapse, excluding mature teratoma. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13402-017-0333-9) contains supplementary material, which is available to authorized users. Springer Netherlands 2017-06-13 2017 /pmc/articles/PMC5537315/ /pubmed/28612337 http://dx.doi.org/10.1007/s13402-017-0333-9 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Paper van Agthoven, Ton Eijkenboom, Wil M. H. Looijenga, Leendert H. J. microRNA-371a-3p as informative biomarker for the follow-up of testicular germ cell cancer patients |
title | microRNA-371a-3p as informative biomarker for the follow-up of testicular germ cell cancer patients |
title_full | microRNA-371a-3p as informative biomarker for the follow-up of testicular germ cell cancer patients |
title_fullStr | microRNA-371a-3p as informative biomarker for the follow-up of testicular germ cell cancer patients |
title_full_unstemmed | microRNA-371a-3p as informative biomarker for the follow-up of testicular germ cell cancer patients |
title_short | microRNA-371a-3p as informative biomarker for the follow-up of testicular germ cell cancer patients |
title_sort | microrna-371a-3p as informative biomarker for the follow-up of testicular germ cell cancer patients |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537315/ https://www.ncbi.nlm.nih.gov/pubmed/28612337 http://dx.doi.org/10.1007/s13402-017-0333-9 |
work_keys_str_mv | AT vanagthoventon microrna371a3pasinformativebiomarkerforthefollowupoftesticulargermcellcancerpatients AT eijkenboomwilmh microrna371a3pasinformativebiomarkerforthefollowupoftesticulargermcellcancerpatients AT looijengaleenderthj microrna371a3pasinformativebiomarkerforthefollowupoftesticulargermcellcancerpatients |